-

SOLVD Health Receives New York State Laboratory Approval

SAN DIEGO--(BUSINESS WIRE)--SOLVD Health (SOLVD), a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has received approval from the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) for its San Diego-based laboratory. This approval authorizes SOLVD Health to offer AvertD® for patients in New York, empowering healthcare providers and patients with critical insights to help mitigate the risk of opioid use disorder (OUD).

The New York State Department of Health is recognized for its rigorous standards in clinical laboratory testing, ensuring that approved laboratories meet high benchmarks for accuracy, reliability, and patient safety. SOLVD Health’s AvertD® genetic test, already FDA-approved, is designed to assess individual genetic susceptibility to OUD, providing valuable information to guide personalized pain management strategies.

"Securing New York State approval is a pivotal step in our mission to expand access to genetic testing that can help address the opioid crisis," said SOLVD Health founder and CEO Dr. Keri Donaldson. "This expansion enables more healthcare providers and patients to benefit from personalized health insights that can inform decisions about pain management and potentially prevent adverse outcomes."

As the healthcare industry continues to seek solutions to combat the ongoing opioid epidemic, AvertD offers clinically validated genetic insights that can help them advise pain management decisions before opioid therapy begins. This approval advances SOLVD Health's mission to translate complex biological signals into actionable patient data, empowering individuals, and healthcare providers to make more informed health decisions.

About SOLVD Health

SOLVD Health is a privately held company focused on preventing disease by making contextual health information accessible to everyone. Through the development of insights-based health tools, SOLVD Health enables individuals and their providers to make better decisions about their health and the health of their families. SOLVD Health accomplishes this by translating complex biological signals into actionable patient data that can point the way to better health. To learn more about SOLVD Health, its solutions, and career opportunities, visit www.solvdhealth.com.

Contacts

Media:
Valerie Melucci
Vice President of Marketing, SOLVD Health
pr@solvdhealth.com

Investors:
Mark Hazeltine
Chief Financial Officer, SOLVD Health
investors@solvdhealth.com

SOLVD Health


Release Versions

Contacts

Media:
Valerie Melucci
Vice President of Marketing, SOLVD Health
pr@solvdhealth.com

Investors:
Mark Hazeltine
Chief Financial Officer, SOLVD Health
investors@solvdhealth.com

Social Media Profiles
More News From SOLVD Health

SOLVD Health Announces FDA Approval to Expand AvertD® Sample Collection to Include Blood, Enabling Broad Availability of the First and Only FDA‑Approved Genetic Test Indicated to Assess Genetic Risk of OUD Prior to First Oral Opioid Prescription

SAN DIEGO--(BUSINESS WIRE)--SOLVD Health, a privately held company focused on preventing disease through actionable and personalized health information, today announced broad availability of AvertD® following FDA approval to expand sample collection to include venous whole blood. AvertD is the first and only FDA‑approved genetic test indicated to assess genetic risk of opioid use disorder (OUD) prior to first exposure to oral opioids for acute pain. AvertD is a qualitative genotyping test that...

SOLVD Health’s Pharmacogenomics Test Receives New York State Department of Health Approval

SAN DIEGO--(BUSINESS WIRE)--SOLVD Health, a patient intelligence company pioneering precision medicine through advanced genetics and AI-driven insights, announced today that its pharmacogenomics (PGx) test PreScript™ has received approval from the New York State Department of Health’s Clinical Laboratory Evaluation Program (CLEP). This milestone enables SOLVD Health to offer its PGx testing services to healthcare providers and patients across New York State, one of the most rigorously regulated...

SOLVD Health Publishes Peer-Reviewed Framework to Advance Clinical Use of Genomic Data

SAN DIEGO--(BUSINESS WIRE)--SOLVD Health, a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has published a peer-reviewed article in the International Journal of Molecular Sciences on best practices for the clinical use of genome-wide association study (GWAS) data. The article provides guidance for integrating imputed genetic information into healthcare in a way that supports accuracy, transparency, and clinical utility. Co-authored by...
Back to Newsroom